PTPRC and cancer: The data showed that CD45+ cells exhibited higher level of STING activation over CD45- populations, indicating that lymphocytes, rather than cancer or stromal cells, may be the primary targets for STING-mediated immunomodulation; thus, host STING is necessary for the combination therapy mediated anti-tumor immunity (Figure S3C).